[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-dysfunction-associated-steatotic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-dysfunction-associated-steatotic-liver-disease":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,73,110,148,179,207,236,263,291,315,345,367,389,418,438,462,489,524,547,572,599,620,645,673,710],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":46,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100526751","effect-of-endoscopic-sleeve-gastroplasty-in-patients-with-obesity-and-mash-a-randomized-controlled-trial-100526751",false,"NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist","ALL","18 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Obesity","Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Weight Loss","Insulin Resistance","Insulin Sensitivity","Insulin Sensitivity\u002FResistance","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[47,48,49,50,51,52,53,54,55,56,57,58,59],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","RECRUITING","2026-06-23",{"date":63,"type":64},"2026-06-25","ACTUAL",{"date":66,"type":64},"2025-06-24",{"date":68,"type":21},"2028-06",{"name":70,"class":71},"Pichamol Jirapinyo, MD, MPH","OTHER",2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100605631","phase-3-a-master-protocol-of-multiple-agents-in-adults-with-metabolic-dysfunction-associated-steatotic-liver-disease-synergy-outcomes-100605631","NCT07165028","A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)","A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes","Inclusion Criteria:\n\n* Have liver fat content ≥8%\n* Have ELF score of ≥9 and ≤10.8 at screening\n* Have VCTE LSM ≥10 kilopascal (kPa) and \\\u003C20 kPa at screening\n\nExclusion Criteria:\n\n* Have any other type of liver disease other than MASLD\n* Have a body mass index (BMI) \\\u003C25 kilogram per square meter (kg\u002Fm2)\n* Prior decompensated liver disease (history of esophageal\u002Fgastric varices, ascites, hepatic encephalopathy)\n* Have lost more than 11 pounds within the 3 months prior to screening\n* Have a hemoglobin A1c (HbA1c) greater than 10%\n* Have type 1 diabetes",{"count":81,"type":21},4500,[83],"PHASE3","The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression.\n\nOnce the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.",[31],[87,88,55,89,90,91,92,93,94,95,96,97,98,99],"Nonalcoholic Steatohepatitis","NASH","Fatty Liver Disease","SLD","Metabolic Dysfunction-Associated Fatty Liver Disease","MAFLD","Non-alcoholic Fatty Liver Disease","NAFLD","Hepatic Steatosis","Liver Related Outcomes","GLP1","Incretin","Non-Invasive Test","2026-06-19",{"date":61,"type":64},{"date":103,"type":64},"2025-10-15",{"date":105,"type":21},"2032-08",{"name":107,"class":108},"Eli Lilly and Company","INDUSTRY",562,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":122,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100641243","automated-passive-case-finding-for-advanced-liver-fibrosis-in-masld-the-liverseek-programme-100641243","NCT07658755","Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme","Towards Universal Screening for Metabolic Dysfunction-Associated Liver Fibrosis in Primary Care: Evaluation of a Single-Step, Laboratory Informatión System-Driven Automated Case-Finding Strategy (LiverSeek)","LiverSeek","Inclusion Criteria:\n\n1. Age between 50 and 75 years (inclusive)\n2. Routine blood test processed in the Clinical Biochemistry Laboratory of Hospital General Universitario Gregorio Marañón, ordered by a primary care physician in one of the 11 affiliated SERMAS primary care centres\n3. Presence of at least one of the following metabolic risk factor combinations:\n\n   * ALT above the upper limit of normal AND HbA1c ≥6.5%\n   * ALT above the upper limit of normal AND BMI \\>30 kg\u002Fm²\n   * BMI \\>30 kg\u002Fm² AND HbA1c ≥6.5%\n\nExclusion Criteria:\n\n1. Age \\\u003C50 years or \\>75 years\n2. Known pre-existing liver disease (significant or advanced fibrosis, cirrhosis, hepatocellular carcinoma, prior liver transplantation)\n3. Prior fibrosis assessment within the preceding 12 months.","50 Years","75 Years",{"count":121,"type":21},3000,"24 Months","OBSERVATIONAL","LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care. The programme operates through the Laboratory Information System (LIS; Modulab\u002FBiwer Analytics) of the Clinical Biochemistry Laboratory at Hospital General Universitario Gregorio Marañón (HGUGM), covering approximately 350,000 inhabitants across 11 peri-urban primary care centres affiliated to SERMAS (Servicio Madrileño de Salud) in Madrid, Spain.\n\nWhen a high-risk patient (age 50-75 years with ≥1 of: ALT above ULN + HbA1c ≥6.5%; ALT above ULN + BMI \\>30; BMI \\>30 + HbA1c ≥6.5%) undergoes a routine blood test in primary care, the LIS automatically calculates FIB-4. If FIB-4 \\>1.30, the system reflexively orders ELF and MASEF from the same serum sample, without any action required from the primary care clinician. Patients with a positive second-step NIT (ELF ≥9.8 or MASEF ≥0.33) receive an automatic alert directing them to the Hepatology Advanced Practice Nurse for VCTE (FibroScan) and clinical evaluation.\n\nThe primary objective is to evaluate the prevalence of hepatic fibrosis in the high-risk population using this single-step automated strategy. Secondary objectives include head-to-head diagnostic comparison of FIB-4+ELF vs FIB-4+MASEF vs FIB-4+FAST for histologically-confirmed endpoints (significant fibrosis ≥F2, advanced fibrosis ≥F3, at-risk MASH), evaluation of the Liver Risk Score, and a health-economic analysis. A sub-study evaluates a nurse-led structured lifestyle intervention in NIT-positive patients.",[31,29,126,127,27,128],"Non-alcoholic Fatty Liver Disease NAFLD","Type 2 Diabetes Mellitus","Obesity Type 2 Diabetes Mellitus",[33,92,94,130,131,132,133,134,135,136,137],"liver fibrosis","FIB-4","ELF","MASEF","screening","passive screening","advanced practice nurse","lifestyle intervention","2026-06-14",{"date":140,"type":64},"2026-06-22",{"date":142,"type":64},"2024-10-01",{"date":144,"type":21},"2027-09-01",{"name":146,"class":71},"Hospital General Universitario Gregorio Marañon",1,{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100638856","phase-2-effects-of-short-term-perioperative-daidzein-intervention-on-liver-histopathology-in-patients-with-masld-100638856","NCT07623044","Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD","Short-Term Daidzein Intervention in MASLD","DAIMAS","Inclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* Male or female participants.\n* Scheduled to undergo elective laparoscopic cholecystectomy or other benign biliary surgery for benign biliary disease.\n* Diagnosis of metabolic dysfunction-associated steatotic liver disease based on hepatic steatosis shown by liver biopsy or imaging, including controlled attenuation parameter, ultrasound, or magnetic resonance imaging, together with at least one cardiometabolic risk factor.\n* Expected preoperative window of at least 28 days before surgery.\n* Able and willing to provide written informed consent.\n* Willing to provide blood samples, urine samples, and intraoperative liver tissue samples.\n* Able and willing to avoid soy-containing foods during the study period, including soybeans, edamame, black soybeans, soy milk, tofu, dried tofu, tofu skin, yuba, tofu pudding, natto, miso, fermented soybeans, tempeh, and other traditional or fermented soy products.\n\nExclusion Criteria:\n\n* Viral hepatitis, autoimmune liver disease, drug-induced liver injury, Wilson disease, or other clearly defined chronic liver diseases.\n* Significant alcohol consumption, defined as more than 140 g per week for women or more than 210 g per week for men.\n* Liver cirrhosis, decompensated liver disease, or hepatobiliary malignancy.\n* Use of antibiotics, probiotics, soy isoflavone-containing products, or hormone-like dietary supplements within 4 weeks before enrollment.\n* Treatment within 3 months before enrollment that may substantially affect body weight or the severity of fatty liver disease.\n* Known allergy to soy products, daidzein, or isoflavones.\n* Pregnancy or breastfeeding.\n* Any condition that, in the opinion of the investigator, makes the participant unsuitable for this study.","70 Years",{"count":158,"type":21},44,[160],"PHASE2","This clinical trial aims to learn whether daidzein can improve liver tissue changes in adults with metabolic dysfunction-associated steatotic liver disease, also called MASLD. MASLD is a liver condition linked to extra fat in the liver and metabolic problems such as obesity, diabetes, abnormal blood lipids, or high blood pressure.\n\nDaidzein is a natural compound found in soy. Earlier laboratory studies suggest that daidzein may help protect the liver. This study will test whether taking daidzein for a short time before surgery can improve liver tissue findings in people with MASLD.\n\nThe main questions this study aims to answer are:\n\nDoes short-term daidzein treatment improve liver tissue injury in people with MASLD? Is daidzein safe and well tolerated before surgery? Are changes in blood or urine equol levels related to the effects of daidzein? Equol is a substance made by gut bacteria after some people take daidzein.\n\nResearchers will compare people who take daidzein before surgery with people who receive standard care without daidzein.\n\nParticipants will:\n\nBe adults with MASLD who are scheduled for elective gallbladder surgery or another benign biliary surgery.\n\nBe randomly assigned to take daidzein or to receive standard care without daidzein.\n\nTake daidzein by mouth for 28 days before surgery if assigned to the daidzein group.\n\nAvoid soy foods during the study period. Provide blood and urine samples. Have a small liver tissue sample collected during surgery. Be followed for safety and recovery after surgery.\n\nThe liver tissue sample will be used to check liver fat, inflammation, and liver cell injury. Researchers will also study markers related to liver injury, immune activity, and how the body responds to daidzein.",[31],[164,165,166,167,168],"Metabolic dysfunction-associated steatotic liver disease","Daidzein","Ferroptosis","Randomized controlled trial","Soy isoflavone","NOT_YET_RECRUITING","2026-06-01",{"date":172,"type":64},"2026-06-03",{"date":174,"type":21},"2026-05-21",{"date":176,"type":21},"2026-08-10",{"name":178,"class":71},"Eastern Hepatobiliary Surgery Hospital",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":147},"100628274","phase-2-smart-diets-for-masld-100628274","NCT07459504","SMART Diets for MASLD","A Sequential Multiple Assignment Randomized Trial of Diet Treatments for Hepatic Steatosis and Cardiometabolic Risk in Youth","Inclusion Criteria:\n\n* Children 11 to 17-years-old at the time of consenting\n* Hepatic Steatosis by MRI greater than or equal to 8% on baseline MRI\n* At least 1 of the following cardiometabolic risk factors: BMI greater than or equal to 85th percentile for age\u002Fsex or WC greater than 95th percentile, Abnormal cholesterol or triglyceride levels, Blood pressure BP greater than or equal to 95th percentile OR greater than or equal to 130\u002F80 and\u002For signs of insulin resistance (Acanthosis Nigricans OR HOMA-IR of greater 2.0 and greater 2.6 in prepubertal and pubertal children, respectively, Fasting Insulin Level of 10 pIU\u002FmL in prepubertal children and of 17 pIU\u002FmL and 13 pIU\u002FmL in pubertal girls and boys, respectively, OR Prediabetes)\n* ALT greater than or equal to 40 U\u002FL\n* Currently consumes greater than or equal to 2 eight-ounce sugar drinks (or juice) per week.\n* Patients of childbearing potential agrees to use adequate one or more effective methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\n* Patients who are taking medications that can affect insulin (e.g., metformin, corticosteroids), most be on a stable dosage for at least 3 months prior to enrollment of the trial.\n* Written informed consent from parent or legal guardian, assent from child.\n\nExclusion Criteria:\n\n* Patients with Diagnosed Type 2 or Type 1 Diabetes Mellitus (T2DM) or HbA1c of \\>6.5 mg\u002FdL at baseline\n* Patients diagnosed with or suspected to have a chronic liver disease other than MASLD by screening labs or evaluation (i.e autoimmune, viral). Screening labs are defined as: Hepatitis B surface antigen, Hepatitis C virus total antibody, IgG, ceruloplasmin, and alpha 1 antitrypsin phenotype.\n* Patients unable to complete MRI or Labs required for the study.\n* Current participation in another clinical trial\n* Current participation in a weight loss program or obesity treatment program or clinic\n* Cancer or history of cancer within 5 years\n* Severe illness that required hospitalization in the last 60 days\n* Use of medications known to cause liver steatosis (TPN, amiodarone, chronic oral steroids, etc.)\n* Patients with implanted metal devices that are not compatible with magnetic resonance imaging (MRI).\n* Intellectual disability or major psychiatric disorder limiting informed assent\n* Clinical evidence of cirrhosis or advanced liver disease by any one of the following abnormal labs: (Hemoglobin less than 10 g\u002FdL, White blood cell less than 3,500 cells\u002Fmm, Neutrophil count less than 1,500 cells\u002Fmm3 of blood, Platelets less than 130,000 cells\u002Fmm3 of blood, Direct bilirubin greater than 1.0 mg\u002FdL)\n* Elevated total bilirubin except if known to have Gilbert's syndrome and direct bilirubin in normal range.\n* Albumin less than 3.2 g\u002FdL\n* A history of international normalized ratio (INR) greater than 1.4\n* AST or ALT greater than 250 IU\u002FdL.\n* Compensated or decompensated cirrhosis with evidence of portal hypertension.\n* Patients is pregnant or breastfeeding.\n* Patients who have been enrolled in a recent clinical trial and had the last dose of investigational product within 30 days or 5 half-lives of the study drug, whichever is longer.","11 Years","17 Years",{"count":189,"type":21},102,[160],"This phase 2 trial is a single-site sequential, multiple assignment, randomized trial (SMART) to test and construct a high-quality adaptive intervention of essential amino acids (EAA) and\u002For Low Sugar Diet for children with metabolic dysfunction associated steatotic liver disease (MASLD) and increased cardiometabolic risk. The basis for the trial includes high-quality pilot data in both EAA for hepatic steatosis and a low sugar diet for hepatic steatosis. In the trial, children aged 11-17 years old will be eligible to participate if their BMI is greater than or equal to 95th% at baseline and hepatic steatosis is greater than or equal to 8% at baseline by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) because this is the most common age group diagnosed with metabolic-dysfunction associated steatotic liver disease.",[193],"Metabolic-dysfunction Associated Steatotic Liver Disease",[33,195,196,197,198],"Adolescents","Liver","Sugar","Amino acid supplement","2026-05-28",{"date":170,"type":64},{"date":202,"type":21},"2026-06",{"date":204,"type":21},"2030-12-26",{"name":206,"class":71},"Michigan State University",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100637072","phase-1-safety-tolerability-pharmacokinetic-and-pharmacodynamic-characteristics-of-act500-in-participants-with-metabolic-dysfunction-associated-steatotic-liver-disease-complicated-with-chronic-hepatitis-b-100637072","NCT07589400","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B","A Multicenter, Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-associated Steatotic Liver Disease Complicated With Chronic Hepatitis B.","Inclusion Criteria:\n\n* The participant fully understands the purpose, nature, methods of the trial, and the potential adverse reactions, voluntarily agrees to participate in this study, and signs the informed consent form.\n* Male or female participants aged between 18 and 60 years (inclusive) at the time of signing the informed consent form.\n* Liver fat content ≥10% as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) during the screening period.\n* Liver stiffness measurement (LSM) by FibroScan during the screening period meets 8 kPa ≤ LSM \\\u003C 12 kPa, or liver biopsy results within 6 months prior to screening show stage F2\u002FF3 liver fibrosis.\n* Hepatitis B surface antigen (HBsAg) positive for \\>6 months at screening, or other evidence of chronic hepatitis B (CHB), with HBV DNA \\\u003C 20 IU\u002FmL.\n* Serum alanine aminotransferase (ALT) \\\u003C 5×ULN at screening.\n* Received nucleos(t)ide analog (NAs) therapy for at least 1 year prior to screening and are currently on stable NA therapy (including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, and tenofovir amibufenamide). Stable NAs therapy is defined as receiving the same treatment regimen within 3 months prior to screening.\n* Have at least one of the following metabolic disease risk factors:\n\nBMI ≥24.0 kg\u002Fm\\^2, or waist circumference ≥90 cm (male) and ≥85 cm (female); Prediabetes: fasting blood glucose ≥6.1 mmol\u002FL, or glycated hemoglobin (HbA1c) ≥5.7%; History of type 2 diabetes mellitus; 1.70 mmol\u002FL ≤ fasting serum triglycerides \\\u003C 5.6 mmol\u002FL; Fasting serum high-density lipoprotein cholesterol ≤1.0 mmol\u002FL (male) and ≤1.3 mmol\u002FL (female), or receiving stable-dose lipid-lowering therapy; Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, with systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤100 mmHg; or receiving stable-dose antihypertensive therapy with systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤100 mmHg.\n\n* Both male and female participants must agree to use adequate contraceptive methods, where:\n\nMale participants: agree to use reliable contraceptive measures from the time of signing the informed consent form until 3 months after the last dose, and have no sperm donation plans; Female participants: women of non-childbearing potential; or women of childbearing potential who are not pregnant or breastfeeding, must have a negative serum pregnancy test result at screening and within 1 day prior to the first dose, agree to use reliable contraceptive measures from the time of signing the informed consent form until 3 months after the last dose, and have no oocyte donation plans.\n\nExclusion Criteria:\n\n* Concurrent other liver diseases, including but not limited to hepatitis C, hepatitis D, drug-induced liver disease, alcoholic liver disease, autoimmune liver disease, suspected or confirmed liver cancer, etc.\n* Participants with a previous or current history of other malignant tumors, liver cirrhosis (including imaging-confirmed or suspected cirrhosis, and liver biopsy-confirmed cirrhosis), or evidence of decompensated liver disease (such as ascites, esophagogastric variceal bleeding, hepatic encephalopathy), or with a history of liver transplantation.\n* Participants with a history or current symptoms of severe cardiovascular and cerebrovascular diseases, including but not limited to uncontrolled or severe arrhythmia (ventricular fibrillation, atrial fibrillation, etc.), myocardial infarction, coronary heart disease, uncontrolled hypertension (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg).\n* Participants with persistent and clinically significant medical history of respiratory, nervous, gastrointestinal, immune, hematological or psychiatric diseases, which, in the opinion of the investigator, may impose additional risks on the participant.\n* Participants with type 1 diabetes or poorly controlled type 2 diabetes (fasting blood glucose \\>9 mmol\u002FL within 3 months prior to screening or glycated hemoglobin \\>9.5% at screening), or diabetic patients using hypoglycemic drugs other than metformin and insulin.\n* Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m² (calculated by the CKD-EPI formula) at screening, or with a history of severe renal impairment.\n* Known hemoglobinopathy, hemolytic anemia, sickle cell anemia; or hemoglobin \\\u003C115 g\u002FL in female participants and \\\u003C130 g\u002FL in male participants at screening; or any other conditions judged by the investigator to interfere with hemoglobin detection.\n* Any of the following laboratory abnormalities at screening: alkaline phosphatase (ALP) \\>2 times the upper limit of normal (ULN), total bilirubin (TBIL) \\>1.5 times the ULN, international normalized ratio (INR) \\>1.3, albumin \\\u003C35 g\u002FL, platelet count \\\u003C125×10⁹\u002FL, and serum triglycerides \\>5.6 mmol\u002FL.\n* Participants with body weight gain or loss \\>5% within 3 months prior to screening, or those receiving diet control, bariatric surgery, or using approved anti-obesity medications for weight loss indications.\n* Participants with a history of major trauma or surgery within 3 months prior to screening, or those scheduled to undergo surgery during the study period.\n* Excessive alcohol consumption for 3 consecutive months or more within 1 year prior to screening. Excessive drinking is defined as weekly ethanol intake ≥210 g for males and ≥140 g for females; or with a history of drug abuse\u002Fdependence or drug inhalation\u002Finjection within 1 year prior to screening.\n* Use of drugs with potential therapeutic effects on MASLD\u002FMASH within 3 months prior to screening (e.g., GLP-1 receptor agonists, DPP4 inhibitors, SGLT2 inhibitors, FGF21 analogues, resmetirom, etc.), or drugs that may induce MASLD\u002FMASH (e.g., amiodarone, methotrexate, tetracyclines, tamoxifen, estrogen at doses exceeding hormone replacement therapy, anabolic steroids, valproic acid, and other known hepatotoxic drugs); use of drugs that may affect the efficacy of hepatitis B treatment within 6 months prior to screening (e.g., anti-HBV drugs other than NAs, interferons, systemic immunomodulators, hepatitis B vaccines, etc.), or any other medications deemed by the investigator to interfere with the study.\n* Participation in other clinical drug trials within 6 months prior to screening.\n* Any positive result for human immunodeficiency virus antibody (HIV-Ab), hepatitis C virus antibody (HCV RNA test is required if positive, with the value below the quantitative lower limit of the local study center), hepatitis D virus antibody, or treponema pallidum antibody during the screening period.\n* Participants with allergic reactions to excipients of ACT500 or drugs with similar chemical structures to ACT500, or other drug allergies deemed ineligible for study participation by the investigator.\n* Any other conditions that render the participant unsuitable for this study as determined by the investigator, or participants who are unable to complete the trial due to personal reasons after signing the informed consent form (ICF).","60 Years",{"count":216,"type":21},24,[218],"PHASE1","This study is a Phase Ib, multicenter randomized, double-blind, dose-escalation, placebo-controlled trial designed to evaluate the safety, tolerability, PK, and PD profiles of multiple-dose ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated with chronic hepatitis B (CHB). The trial plans to enroll 24 participants with MASLD complicated with CHB across three dose cohorts initially, each consisting of 8 participants who will receive oral ACT500 tablets once daily.",[221,222],"Metabolic Dysfunction-associated Steatotic Liver Disease","Chronic Hepatitis b",[221,222,224,225],"ACT500","NM6606","2026-05-11",{"date":228,"type":64},"2026-05-15",{"date":230,"type":21},"2026-05-30",{"date":232,"type":21},"2027-06-30",{"name":234,"class":108},"Xiamen Amoytop Biotech Co., Ltd.",4,{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":242,"minAge":243,"maxAge":119,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":147},"100622672","impact-of-circadian-exercise-on-metabolic-dysfunction-associated-steatotic-liver-disease-in-postmenopausal-women-100622672","NCT07386665","Impact of Circadian Exercise on Metabolic Dysfunction-Associated Steatotic Liver Disease in Postmenopausal Women","Inclusion Criteria:\n\n* Women aged 45-75 years, postmenopausal for at least two years (stage +1a)\n* Body Mass Index (BMI) \\> 25 and \\\u003C 40 kg\u002Fm²\n* Diagnosed hepatic steatosis (via ultrasound hyperechogenicity, FibroScan CAP score \\>280, or histological confirmation)\n* Sedentary lifestyle (no regular structured exercise)\n* Willingness to be randomized and adhere to study procedures, including all assessments and visits\n* Sufficient Spanish proficiency to understand and follow study instructions\n* Consent to store biological samples for future research\n* Participants should have a healthy circadian rhythm\n\nExclusion Criteria:\n\n* Contraindications for MRI (e.g., claustrophobia, pacemaker, metal implants)\n* History of major cardiovascular, endocrine, neurological, or kidney disease, or any clinical abnormalities (to be judged by the study physician)\n* First-degree family history of sudden cardiac death\n* Alcohol or substance abuse\n* Psychiatric, psychotic, eating, or sleep disorders (to be judged by the study physician)\n* Prior bariatric surgery, diagnosed HIV\u002FAIDS, or inflammatory\u002Fautoimmune diseases\n* Cancer or any medical condition where exercise is contraindicated (to be judged by the study physician)\n* Recent or unstable metabolic conditions (e.g., diabetes, recent medication changes, or use of drugs affecting metabolism)\n* Recent (\\\u003C3 months) use of antibiotics, statins, glucocorticoids, hormonal therapies, amiodarone, or myelosuppressive agents\n* Participation in weight-loss programs or special diets (e.g., ketogenic, high-carb)\n* Shift workers or caregivers with frequent nocturnal disruptions","FEMALE","45 Years",{"count":245,"type":21},63,[24],"Type of Study: Clinical Trial\n\nGoal: The goal of this clinical trial is to investigate how performing exercise at different times of day (morning vs. evening) affects liver fat, cardiometabolic health, and gut microbiota in postmenopausal women.\n\nParticipant Population\u002FHealth Conditions: The study will involve 63 sedentary postmenopausal women (aged 45-75) diagnosed with metabolic dysfunction-associated steatotic liver disease.\n\nMain Questions: The main questions this study aims to answer are:\n\n* Does morning exercise reduce hepatic fat more effectively than evening exercise?\n* How does time-of-day-specific exercise influence cardiometabolic markers?\n* Do changes in gut microbiota contribute to the metabolic effects of exercise timing?\n\nParticipants Will:\n\nBe randomized into one of three groups: morning exercise, evening exercise, or a usual-care control group.\n\nFollow the assigned regimen for 12 weeks. The exercise groups will perform supervised aerobic and resistance training three times per week.\n\nProvide blood, stool, and imaging data before and after the intervention to determine the effects of the intervention.\n\nComparison Group:\n\nResearchers will compare the effects of morning vs. evening exercise (and usual care) on hepatic fat reduction and cardiometabolic improvement, as well as changes in gut microbiota.",[31,249,250],"Cardiometabolic Diseases","Exercise",[250,252,253,254],"Metabolism","Health","Women","2026-05-04",{"date":257,"type":64},"2026-05-08",{"date":170,"type":21},{"date":260,"type":21},"2027-12",{"name":262,"class":71},"Universidad de Almeria",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":147},"100630430","mpv-as-a-predictor-for-acs-in-patients-with-masld-100630430","NCT07487571","MPV as a Predictor for ACS in Patients With MASLD","Mean Platelet Volume as a Predictor for Acute Coronary Syndrome in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease","MPV\u002FACS MASLD","Inclusion Criteria:\n\n* Adult patients aged ≥18 years.\n* Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) based on clinical, laboratory, and imaging criteria).\n* Patients diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) for Group I.\n* MASLD patients without clinical or electrocardiographic evidence of acute coronary syndrome for Group II.\n* Patients who provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with chronic liver diseases other than MASLD (e.g., viral hepatitis, autoimmune hepatitis, alcoholic liver disease).\n* Patients with known hematological disorders affecting platelet count or function.\n* Patients receiving antiplatelet or anticoagulant therapy prior to blood sampling.\n* Patients with active infection, inflammatory diseases, or malignancy.\n* Patients with chronic kidney disease or end-stage renal failure.\n* Pregnant or lactating females.",{"count":272,"type":21},60,"The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.",[31,275],"Acute Coronary Syndromes (ACS)",[277,278,279,280,281],"Mean platelet volume","Cardiovascular risk","Platelet activation","Metabolic syndrome","Liver staetosis","2026-04-30",{"date":284,"type":64},"2026-05-06",{"date":286,"type":21},"2026-05-05",{"date":288,"type":21},"2026-12-01",{"name":290,"class":71},"Sohag University",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100580385","phase-1-a-study-to-evaluate-aln-cideb-in-adult-participants-with-metabolic-dysfunction-associated-steatotic-liver-disease-or-with-metabolic-dysfunction-associated-steatohepatitis-masldmash-100580385","NCT06836609","A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD\u002FMASH)","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Key Inclusion Criteria:\n\n1. Part A: 18 to 55 years at Screening Visit 1 with MASLD, at Screening Visit 1 Part B: 18 to 65 years at Screening Visit 1 with a diagnosis of MASH, at Screening Visit 1\n2. Body Mass Index (BMI) ≥30 kg\u002Fm2 and ≤40 kg\u002Fm2 at Screening Visit 1\n3. Controlled-Attenuation Parameter (CAP) ≥285 dB\u002Fm by FibroScan during screening as described in the protocol\n4. Liver fat content ≥8.5% by MRI-PDFF during screening\n5. If on anti-hypertensive and\u002For lipid lowering medications and\u002For glucose lowering medications, must be on generally stable dose(s) for at least 12 weeks prior to screening and no changes to the dose(s) are anticipated during the study\n6. Part B: A diagnosis of MASH documented in the participant's medical history, or a clinical suspicion of MASH based on non-invasive biomarkers (eg, evidence of fatty liver on imaging and elevated liver enzymes) and clinical risk factors, including having a history of 2 or more elements of metabolic syndrome, as defined in the protocol\n7. Part B: Screening percutaneous liver biopsy NAFLD Activity Score (NAS) ≥3 and fibrosis stage, as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Known historical or current diagnosis of portal hypertension or cirrhosis based on clinical assessment, imaging, and\u002For liver biopsy\n2. Known historical or current diagnosis of other forms of chronic liver disease, as defined in the protocol\n3. Prior or current suspected or known drug-induced liver injury within 1 year prior to screening\n4. History of liver transplant, current placement on a liver transplant list, or Model for End-stage Liver Disease (MELD) score \\>12\n5. Contraindication to MRI examinations, such as persons with cardiac pacemaker and implants made of metal, severe claustrophobia, size restrictions, or other contraindications for MRI\n6. Liver stiffness measurement, laboratory parameter assessment, estimated Glomerular Filtration Rate (GFR), and evidence of uncontrolled hypertension, as defined in the protocol\n7. Evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B Virus (HBV) infection, or Hepatitis C Virus (HCV) infection during screening, as described in the protocol\n8. History of Type 1 Diabetes\n9. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions, within approximately 5 years prior to randomization or planned during the study period\n\nNOTE: Other protocol-defined inclusion\u002Fexclusion criteria apply.","65 Years",{"count":20,"type":21},[218,160],"This study is researching an experimental drug called ALN-CIDEB, also referred to as \"study drug\". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting liver conditions caused by having too much fat in the liver.\n\nThe aim of the study is to see how safe and tolerable the study drug is.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How the study drug works to change liver fat content\n* How much study drug and study drug metabolites (byproducts of the body breaking down the study drug) are in the blood at different times",[31,32],[304,33,34],"Obese","2026-04-22",{"date":307,"type":64},"2026-04-27",{"date":309,"type":64},"2025-04-28",{"date":311,"type":21},"2027-05-15",{"name":313,"class":108},"Regeneron Pharmaceuticals",3,{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":323,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":324,"targetDuration":326,"studyType":123,"phases":4,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":147},"100633725","samsung-s-viscosity-vs-canon-dispersion-slope-in-steatotic-liver-disease-savid-sld-100633725","NCT07530419","Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)","Prospective Evaluation of Samsung Medison 2D Shear Wave Elastography Viscoelasticity Parameters in Patients With Steatotic Liver Disease Using Canon Dispersion Slope Imaging as Reference Standard: A Single-Center Non-Interventional Observational Study","SAVID-SLD","Inclusion Criteria:\n\n* \\[Cohort A - Healthy reference\\]\n\n  * Adults ≥18 years old\n  * Currently undergoing living-donor evaluation at SNUH\n  * Donor evaluation confirms (a) hepatic steatosis \\\u003C5% by imaging or biopsy, (b) normal AST\u002FALT, and (c) absence of chronic liver disease (HBV, HCV, autoimmune, cholestatic, etc.)\n  * Provided written informed consent \\[Cohort B + C - Steatotic liver disease\\]\n  * Adults ≥18 years old\n  * Sonographically suspected or confirmed hepatic steatosis on B-mode ultrasound, scheduled for clinical abdominal ultrasound\n  * Serum AST\u002FALT results available within 6 weeks of ultrasound, or scheduled\n  * Provided written informed consent\n\nExclusion Criteria:\n\n* • Significant alcohol intake within the past 2 years (\\>30-60 g\u002Fday for males, \\>20-50 g\u002Fday for females)\n\n  * Diagnosed or strongly suspected chronic liver disease (active HBV\u002FHCV, autoimmune liver disease, cholestatic liver disease, Wilson's disease, hemochromatosis, etc.)\n  * Suspected hepatic failure or decompensated cirrhosis (albumin \\\u003C3.2 g\u002FdL, INR \\>1.3, direct bilirubin \\>1.3 mg\u002FdL)\n  * Ascites, history of variceal bleeding, or acute biliary obstruction rendering stable measurements unfeasible\n  * History of liver malignancy or treatment for liver malignancy\n  * History of liver surgery\n  * Pregnancy or lactation\n  * Inadequate ultrasound image quality due to obesity, bowel gas, or patient inability to cooperate",true,{"count":325,"type":21},95,"1 Week","Steatotic liver disease (SLD) is one of the most common chronic liver diseases worldwide. Distinguishing simple steatosis from metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis is clinically important, but liver biopsy - the current standard - is invasive. Recent ultrasound technology allows noninvasive measurement of tissue viscoelasticity, which has been linked to liver inflammation. Samsung Medison's HERA W12 system (S-Viscosity) and Canon Aplio i800 (Dispersion Slope Imaging) both provide vendor-specific viscoelasticity parameters derived from shear-wave dispersion analysis, but their relationship and agreement have not been compared in SLD patients.\n\nThis prospective single-center observational study will enroll approximately 95-100 participants in three cohorts: (A) 15-20 living-donor candidates as a healthy reference, (B+C) approximately 80 adults with sonographically suspected or confirmed SLD recruited consecutively. SLD participants will be classified post-hoc into low-MASH-risk (Cohort B) and at-risk MASH (Cohort C) subgroups using a multi-parametric stratification combining liver stiffness (LSM), DeepUSFF (deep-learning-based ultrasound fat fraction), and serum AST. All participants will undergo same-day ultrasound examination with both Samsung HERA W12 and Canon Aplio i800. The primary objective is to evaluate the correlation and agreement between Samsung S-Viscosity and Canon Dispersion Slope. Secondary objectives include deriving a normal reference range from the healthy cohort, comparing viscoelasticity parameters across cohorts, and exploring a Modified US-FAST score.",[31,55,29],[330,331,332,333,334,33,34,335],"Shear wave elastography","Viscoelasticity","Dispersion slope","Liver stiffness","Quantitative ultrasound","S-Viscosity","2026-04-08",{"date":338,"type":64},"2026-04-15",{"date":340,"type":21},"2026-04-10",{"date":342,"type":21},"2027-02-28",{"name":344,"class":71},"Seoul National University Hospital",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":147},"100605197","advanced-fibrosis-detection-for-masld-in-primary-care-100605197","NCT07159386","Advanced Fibrosis Detection for MASLD in Primary Care","Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care","Patients\n\nInclusion Criteria:\n\n* Patients with a diagnosis code for MASLD\n* Type 2 diabetes mellitus will\n\nExclusion Criteria:\n\n* All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded.\n* pregnant women.\n\nClinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices.\n\nInclusion criteria:\n\n1\\. All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study.\n\nExclusion criteria:\n\nNone",{"count":353,"type":21},225,[24],"This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.",[221],[40,196,27],"2026-03-30",{"date":360,"type":64},"2026-03-31",{"date":362,"type":64},"2026-03-16",{"date":364,"type":21},"2030-09",{"name":366,"class":71},"Medical University of South Carolina",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":33,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":147},"100630538","phase-1-developing-microbial-therapy-for-masld-from-mechanism-to-clinical-validation-100630538","NCT07488975","Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation","Development of Microbial Therapeutics for Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Investigations to Clinical Trials","Inclusion Criteria:\n\n* Fibroscan，CAP ≧ 260db\u002Fm\n\nExclusion Criteria:\n\nA. Pregnant women or women who are breastfeeding. B. Use of probiotics and prebiotic-related products (including yogurt, yogurt, Yakult, etc.) within 14 days before the screening visit.\n\nC. Patients who have used antibiotics (except skin lotions) or antifungal drugs within 30 days before the screening visit.\n\nD. Use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) within six months prior to the screening visit.\n\nE. Use of drugs that may affect the evaluation index within 14 days before the screening visit, during the screening visit, or during the planned trial period, such as steroids, immunosuppressants, or anti-inflammatory drugs, or drugs containing ingredients for treating hepatitis or affecting fat metabolism, including HMG-CoA reductase inhibitors (statins), fibrates, silymarin, thiazolidinediones, metformin, cholestyramine, ezetimibe, orlistat, and sodium-glucose transporter type 2 inhibitors (SGLT2i). This restriction does not apply if the above-mentioned drugs have been used continuously for more than six months and the dosage is not changed during the trial.\n\nF. Those who have had severe gastrointestinal infection diarrhea symptoms within 14 days before the screening visit (more than three watery stools in 24 hours).\n\nG. Have the following medical history or laboratory abnormalities:",{"count":375,"type":21},40,[218],"Metabolic dysfunction-associated steatotic liver disease (MASLD), redefined in 2020, is an improved diagnostic standard evolved from non-alcoholic fatty liver disease (NAFLD), emphasizing the correlation between hepatic steatosis and metabolic dysfunction. Compared to NAFLD, which relies on exclusion-based diagnosis, MASLD criteria enhance population homogeneity in studies and accommodate patients with coexisting liver diseases, thereby improving the efficiency and relevance of drug development. MASLD affects approximately one-quarter of the global population. If left untreated, it may progress to liver fibrosis, cirrhosis, or hepatocellular carcinoma. Given its high clinical burden and the current lack of FDA-approved therapies, effective treatments for MASLD are urgently needed.\n\nPrevious studies suggest that diet and gut microbiota play crucial roles in the pathogenesis of MASLD. Dietary composition influences microbial balance and intestinal barrier function. In dysbiosis, gut-derived harmful substances such as pathogen-associated molecular patterns (PAMPs) and microbiota-derived metabolites (MDMs) may translocate via a leaky gut to the liver through the portal vein, contributing to hepatic injury. These processes, often described as the gut-liver axis, remain incompletely understood.\n\nAnimal studies have shown that dietary components regulating gut microbiota may help alleviate MASLD. While clinical evidence remains limited, incorporating microbiota-modulating and immune-regulating food ingredients holds potential. Next-generation probiotics have demonstrated benefits in improving hepatic lipid metabolism and modulating gut microbiota, potentially slowing MASLD progression through gut-liver axis modulation.\n\nOur previous research investigated a pasteurized Akkermansia muciniphila strain, NTUH\\_Amuc03 (pAKK\\_LWHK0003), which attenuated fatty liver progression in preclinical models. In mice subjected to a high-fat, high-fructose, high-cholesterol diet, pAKK\\_LWHK0003 administration resulted in reduced body weight, improved dyslipidemia, lowered NAFLD activity scores, and improved HOMA-IR. These findings support the potential of pAKK\\_LWHK0003 in slowing MASLD progression.\n\nThis study aims to evaluate further the clinical efficacy and safety of pAKK\\_LWHK0003 in individuals with MASLD.",[31],[33,34],"2026-03-18",{"date":382,"type":64},"2026-03-23",{"date":384,"type":64},"2025-01-22",{"date":386,"type":21},"2026-12-31",{"name":388,"class":108},"Leeuwenhoek Laboratories Co. Ltd.",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":414,"leadSponsor":416,"locationsCount":147},"100627554","a-large-language-model-based-chatbot-for-alcohol-reduction-in-patients-with-metabolic-alcohol-related-liver-disease-100627554","NCT07450144","A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease","A Large Language Model-based Chatbot for Alcohol Reduction Counseling in MetALD Patients: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1\\. Hong Kong residents aged 18 years or above 2. Diagnosed of MASLD:\n\n1. Evidence of hepatic steatosis (fat accumulation in the liver) confirmed by imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), or liver biopsy\n2. Presence of metabolic dysfunction, indicated by at least one of the following:\n\n   * Overweight or obesity (body mass index \\[BMI\\] ≥25 kg\u002Fm²),\n\n     * Type 2 diabetes mellitus, ③Dyslipidemia (elevated triglycerides \\[≥150 mg\u002FdL\\] or low high-density lipoprotein \\[HDL\\] cholesterol \\[\\\u003C40 mg\u002FdL for men, \\\u003C50 mg\u002FdL for women\\]), ④Hypertension (blood pressure ≥130\u002F85 mmHg or use of antihypertensive medication).\n\n       * Metabolic syndrome as defined by established criteria (e.g., International Diabetes Federation \\[IDF\\], Adult Treatment Panel III \\[ATP III\\]) 3. Alcohol consumption: males who drink 210-420 g\u002Fweek (≈263-525 ml), female who drink 140-350 g\u002Fweek (≈175-438 ml) 4. Intention to reduce\u002Fquit alcohol 5. Able to read and communicate in Chinese 6. Own a smartphone with internet access\n\nExclusion Criteria:\n\n1. Diagnosed with mental disease or cognitive impairments, or\n2. Participating in other ongoing clinic trials",{"count":397,"type":21},50,[24],"The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease. Specific objectives include:\n\n1. To assess how many MetALD patients accept the invitation to participate in the trial\n2. To assess the retention rate of the participants through 3 and 6 months after treatment initiation\n3. To assess the acceptability of the LLM-based chatbot in terms of participants' compliance and usability rating\n4. To estimate the intervention effect on alcohol reduction\n5. To explore the participants' perception and experiences in the chatbot",[31,401],"Metabolic Alcohol-Related Liver Disease",[403,404,405,406,407,408,409,410,411],"drinking","Chinese","mHealth","WhatsApp","BCTs","COM-B model","cirrhosis","Large language model","AI-based chatbot",{"date":382,"type":64},{"date":380,"type":21},{"date":415,"type":21},"2027-07-22",{"name":417,"class":71},"The University of Hong Kong",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":323,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":424,"targetDuration":426,"studyType":123,"phases":4,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":436,"locationsCount":147},"100626555","the-establishment-of-hong-kong-diabetes-steatotic-liver-disease-register-100626555","NCT07437157","The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register","Inclusion Criteria:\n\n* T2DM.\n* Aged ≥ 18 years.\n* Able and willing to give Informed written consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* Terminal illness such as malignancy with limited life expectancy.\n* Any condition, as judged by the investigators, as ineligible to participate in this study.",{"count":425,"type":21},1000,"15 Years","Liver is an important organ in maintaining energy homeostasis. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease locally and globally. MASLD and type 2 diabetes mellitus (T2DM) are closely related with alarmingly high prevalence of MASLD in people with T2DM, along with the escalated risk of adverse clinical outcomes. Our group has reported that around 70% of people with T2DM have increased controlled attenuation parameter (CAP) suggestive of hepatic steatosis and one out of six had advanced liver fibrosis as evidenced by increased liver stiffness measurements (LSM). Despite its prevalence, close relationships and potential consequences, the mechanisms underlying the complex interconnections between MASLD and T2DM are not fully understood. MASLD is associated with a twofold higher risk of developing T2DM, independent of obesity and other common metabolic risk factors. This risk increases with the severity of MASLD, such that patients with more advanced stages of liver fibrosis are at a higher risk of developing T2DM. Moreover, the progression from hepatic steatosis to fibrosis is an important, yet not fully understood, step towards cirrhosis and end-stage liver disease. Identification of clinical predictors and biomarkers to select individuals with MAFLD for close monitoring is pivotal to prevent the sinister outcomes. To date, longitudinal cohorts with paired biobank focused on people with diabetes and comorbid MASLD for investigating the clinical courses and biomarkers for prediction of outcomes are lacking. We hypothesized that Hong Kong Chinese T2DM with comorbid steatotic liver disease have unique clinical courses and special biomarkers for predicting the progression to advanced liver fibrosis. The aims of this study are: 1) establish a prospective cohort of people with T2DM and comorbid steatotic liver disease accompanied with the setting up of a biobank; 2) elucidate the clinical courses and outcomes of Hong Kong Chinese T2DM with comorbid steatotic liver disease; 3) identify potential diagnostic markers of advanced liver fibrosis in people with T2DM and comorbid steatotic liver disease in Hong Kong. The primary outcome measure will be all-cause mortality and secondary outcome measure will be fatal and non-fatal CVD, heart failure, hospitalizations, NT-proBNP levels, and novel diagnostic markers of MASH in people with T2DM comorbid with MASLD.",[31,429],"Type 2 Diabetes (T2DM)","2026-02-25",{"date":432,"type":64},"2026-02-27",{"date":434,"type":64},"2025-06-11",{"date":342,"type":21},{"name":437,"class":71},"Chinese University of Hong Kong",{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":323,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":448,"conditions":449,"keywords":450,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":147},"100626043","using-digital-twin-technology-and-clinical-decision-support-systems-to-improve-the-early-detection-personalised-treatment-and-long-term-monitoring-of-patients-across-the-full-spectrum-of-metabolic-associated-fatty-liver-disease-mafld-100626043","NCT07430501","Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).","AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients","ARTEMIS","INCLUSION CRITERIA:\n\n1. \\- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.\n\n   * Age ≥18 years\n   * Diagnosis of MASLD confirmed by radiological imaging (any type: MR, CT, PET, VCTE, US, USE...) or histology (gold standard, following MASH SAF score)\n   * With at least one follow-up of minimum 1 year after diagnosis of MASLD, with radiological imaging or histology\n2. \\- Clinical Use case 2: MASLD and progression of cardiovascular diseases\n\n   * Age ≥18 years MASLD patients regardless of disease stage of severity (from simple steatosis to cirrhosis)\n   * Patients without known heart disease\n   * Cardiovascular assessment available\n\n3.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.\n\n* Age ≥18 years\n* TIPS indication (Baveno VII), except pre-emptive and salvage TIPS.\n* Recurrent variceal bleeding after failure of the usual pharmacological and endoscopic methods\n* Refractory or recurrent ascites or difficult to treat\n* Refractory Hydrothorax\n* Patients with diagnosis of liver cirrhosis (based on laboratory parameters, clinical, endoscopic, radiological or histological findings), of any aetiology.\n\n3.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.\n\n* Age ≥18 years\n* All patients with cirrhosis (all aetiologies) who were transplanted\n\n  4.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\\* (\\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)\n* Age ≥18 years\n* Diagnosis of HCC (any aetiology)\n* Cross sectional imaging follow-up (any modality) of liver diseases 6 months after treatment\n* Non-cirrhotic or no more than Child-Pugh B cirrhosis.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patients without history of prior HCC\n* Patients with a history of hypertension should be well controlled (\\\u003C 140\u002F90 mmHg) on a regimen of antihypertensive therapy.\n* With a minimum follow-up of two years or until death, after diagnosis of HCC\n\n  5.- Other populations (participation in control arms)\n* Age ≥18 years\n* Subjects presenting cardiac fibrosis, without a known MASLD diagnosis (as controls for use case 2)\n\nEXCLUSION CRITERIA:\n\n1. \\- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.\n\n   * Missing data on blood glucose, BMI and metabolic status.\n   * Patients who have received systemic chemotherapy\n   * Patients with hepatitis B (HBV) and hepatitis C (HCV), alcoholic liver disease (more than 5 years of drinking history, equivalent to alcohol volume ≥ 30g \u002F D in male and ≥ 20g \u002F D in female), drug-induced liver disease or autoimmune hepatitis.\n   * Subjects having a significant risk of bleeding (platelet \\\u003C 50x109 \u002F L, prothrombin activity \\\u003C 50%)\n   * Presence of any other form of chronic liver, at the time of MASLD diagnosis.\n2. \\- Clinical Use case 2: MASLD and progression of cardiovascular diseases\n\n   * Association with another cause of liver disease\n   * History of hepatitis B or C\n   * Already known coronary artery disease\n   * History of cardiovascular events\n\n3.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.\n\n* Non-cirrhosis TIPS\n* Portosinusoidal vascular disease\n* Complete portal vein thrombosis\n* Patients with surgical porto-caval shunts.\n* Patients with evidence of current locally advanced or metastatic malignancy\n* Patients with acute or chronic heart failure (New York Heart Association \\[NYHA\\]).\n* Patients with chronic obstructive pulmonary disease GOLD grade III\u002FIV\n* Patients with chronic kidney disease requiring renal replacement therapy\n* Patients with a known infection with human immunodeficiency virus (HIV) or have clinical signs and symptoms consistent with current HIV infection\n* Patients with previous liver transplantation\n* Patients lost to follow-up and therefore have an incomplete 1-year follow-up\n\n3.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.\n\n* Patients who were transplanted due to acute liver failure.\n* Patients who were already transplanted before (retransplant)\n* Patients who are lost to follow-up in the first 5 years after liver transplant.\n\n  4.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\\* (\\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)\n* Mixed-tumor HCC based on radiological and\u002For pathological examination\n* Uncontrolled inter-current illness or psychiatric illness or social situations that would limit compliance with study requirements.\n* Subjects with history of another primary cancer\n* Fully recovered from any prior surgery and\u002For radiation and none within 2 weeks of initiating treatment.\n* Subjects with active hepatitis B or C on antiviral compounds may remain on such treatment, except for interferon.\n* Subjects with diagnosis of tumor of mixed origin, either from radiological or biopsy report.\n\n  5.- Other populations (participation in control arms)\n* Patients with diagnosis of MASLD",{"count":447,"type":21},7720,"The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops. This model will also help predict heart problem at different stage of the disease.",[31],[33,451,452],"Virtual twins","fatty liver patients","2026-02-17",{"date":455,"type":64},"2026-02-24",{"date":457,"type":21},"2026-02-23",{"date":459,"type":21},"2027-09-02",{"name":461,"class":71},"Hospital Universitari Vall d'Hebron Research Institute",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":298,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":476,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":147},"100558999","phase-1-human-models-of-selective-insulin-resistance-pancreatic-clamp-100558999","NCT06558422","Human Models of Selective Insulin Resistance: Pancreatic Clamp","Inclusion Criteria:\n\n* Men and women, ages 18-65 years\n* Body mass index of 27-50 kg\u002Fm2\n* Able to understand written and spoken English and\u002For Spanish\n* Evidence of insulin resistance, represented by any or all of the following criteria:\n\n  * Meeting either of the American Diabetes Association's definitions for prediabetes or Impaired fasting glucose (IFG) within the previous year and on screening labs:\n\n    1. Prediabetes: Hemoglobin A1c 5.7-6.4%\n    2. IFG: plasma glucose of 100-125 mg\u002FdL after 8-h fast\n* Homeostasis Model of Insulin Resistance (HOMA-IR) score ≥ 2.73\n* Fasting hyperinsulinemia (fasting insulin level ≥ 13 µU\u002FmL) on screening labs\n* Presence of uncomplicated MASLD, defined by vibration-controlled transient elastography (VCTE) as a steatosis score S1-S3 + fibrosis score F0-F2\n* Written informed consent (in English or Spanish) and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations.\n\nExclusion Criteria:\n\n* Unable to provide informed consent in English or Spanish\n* Unwillingness to use only bedpan or urinal to void or to refrain from non-emergent mobile device use during the clamp\n* Documented weight loss of ≥ 5% of baseline within the previous 3 months\n* Abnormal blood pressure (including on treatment, if prescribed)\n\n  * Systolic blood pressure \\\u003C 90 mm Hg or \\> 160 mm Hg, and\u002For\n  * Diastolic blood pressure \\\u003C 60 mm Hg or \\> 100 mm Hg\n* Abnormal resting heart rate: \\\u003C 60 or ≥ 110 bpm\n\n  * Sinus brady- or tachycardia that has been worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion\n* Abnormal screening electrocardiogram (or if on file, performed within previous 90 days)\n* Laboratory evidence of diabetes mellitus:\n\n  * Hemoglobin A1c ≥ 6.5%, and\u002For\n  * Fasting plasma glucose ≥ 126 mg\u002FdL\n* Positive qualitative β-hCG (Human chorionic gonadotropin, β subunit) (i.e., pregnancy test) in women of childbearing potential\n* Positive urine drug screen, except for lawfully prescribed medications and\u002For marijuana\n* Liver function abnormalities (either of the following)\n\n  * Transaminases (AST or ALT) \\> 3.0 x the upper limit of normal\n  * Total bilirubin \\> 1.25 x the upper limit of normal\n* Fasting serum triglycerides at screening ≥ 400 mg\u002FdL\n* Abnormal screening serum electrolytes that are considered potentially significant according to the clinical judgment of the PI\n* Abnormal complete blood count (CBC) (any of the following)\n\n  * Hemoglobin \\\u003C 10 g\u002FdL or hematocrit \\\u003C 30%\n  * Platelet count \\\u003C 100,000\u002FµL\n* Women currently pregnant, measured by serum and\u002For urine β-hCG, or trying to become pregnant\n* Women currently breastfeeding\n* History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes):\n\n  * Hemoglobin A1c ≥ 6.5%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency\n  * Plasma glucose ≥ 126 mg\u002FdL after 8-h fast\n  * Plasma glucose of ≥ 200 mg\u002FdL at 2 h after ingestion of a 75-g glucose load\n  * Random plasma glucose ≥ 200 mg\u002FdL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state\n* History of gestational diabetes mellitus within the previous 5 years\n* Use of most antidiabetic medications within the 30 days prior to screening\n\n  * Excluded: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin\n  * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening\n* Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)\n* Known diagnoses of familial combined hyperlipidemia or familial chylomicronemia syndrome\n* Use of certain lipid-lowering drugs within 30 d prior to screening visit:\n\n  * Fibrates (e.g., fenofibrate, clofibrate, gemfibrozil)\n  * Prescription-strength omega-3 fatty acids (e.g., Lovaza®, Vascepa®)\n* Known, documented history, at the time of screening, of any of the following medical conditions:\n\n  * Pancreatic pathology\n  * Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)\n  * Chronic kidney disease, Stage 3 or higher (estimated glomerular filtration rate \\\u003C 60 mL min-1 1.73 m-2), of any cause\n  * Advanced or severe liver disease (including fibrosis scores of F3-F4 on screening VCTE)\n  * Gallstone disease\n  * Chronic viral illness\n  * Malabsorptive conditions (active)\n  * Active seizure disorder (including controlled with antiepileptic drugs)\n  * Psychiatric diseases causing functional impairment and\u002For requiring use of anti-dopaminergic antipsychotic drugs associated with significant weight gain\u002Fmetabolic dysfunction (e.g., clozapine, olanzapine), monoamine oxidase inhibitors, tricyclic antidepressants, or lithium\n  * Known adrenal disease\n  * Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation\n  * Bleeding disorders, including due to anticoagulation, or significant anemia (see above)\n  * Active malignancy, or hormonally active benign neoplasm\n* Clinical concern for increased risk of volume overload, including due to medications and\u002For heart\u002Fliver\u002Fkidney problems, as listed above\n* Clinical concern for increased risk of hypokalemia, including low potassium on screening labs (i.e., below lower limit of normal), use of certain medications, or any medical conditions listed above\n* Use of certain medications currently or within 30 d prior to screening:\n\n  * Prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for:\n  * Use of drugs prescribed for indications other than the exclusionary diagnoses\u002Fpurposes listed above, e.g., antiepileptic drugs used for non-seizure indications, ACEi (angiotensin-converting enzyme inhibitor) \u002F ARB (angiotensin receptor blocker) used for uncomplicated hypertension rather than for congestive heart failure, etc. Note, as above, that antidiabetic drugs except metformin within 30 days of screening are excluded.\n  * Loop diuretics (furosemide, torsemide, ethacrynic acid)\n  * Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted\n  * Fludrocortisone\n  * Beta blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem)\n* History of certain weight-loss (bariatric) surgery, including:\n\n  * Roux-en-Y gastric bypass\n  * Biliopancreatic diversion\n  * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months\n* Clinical concern for alcohol overuse, including recent documented history during screening and\u002For participant report of regularly consuming more than 2 drinks per day for males or 1 drink per day for females.\n* Positive urine drug screen, with exceptions for:\n\n  * Lawfully prescribed medications\n  * Marijuana\u002FTHC positivity, provided that the participant agrees not to use it during the same period that they will abstain from alcohol\n* History of severe infection or ongoing febrile illness within 14 days of screening\n* Any other disease, condition, or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and\u002For interfere with the analysis of study data.\n* Known allergy\u002Fhypersensitivity to any component of the medicinal product formulations, foods (including soy, dairy, peanuts, tree nuts, or egg), IV infusion equipment, plastics, adhesive or silicone, history of infusion site reactions with IV administration of other medicines, or ongoing clinically important allergy\u002Fhypersensitivity as judged by the investigator.\n* Concurrent enrollment in another clinical study of any investigational drug therapy within 30 days prior to screening or within 5 half-lives of an investigational agent, whichever is longer.",{"count":469,"type":21},36,[218],"This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the impact of lowering insulin levels on hepatic glucose production (HGP) vs de novo lipogenesis (DNL) in people with insulin resistance. The investigators will recruit participants with a history of overweight\u002Fobesity and evidence of insulin resistance (i.e., fasting hyperinsulinemia plus prediabetes and\u002For impaired fasting glucose and\u002For Homeostasis Model Assessment of Insulin Resistance \\[HOMA-IR\\] score \\>=2.73), and with evidence of metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo two pancreatic clamp procedures -- one in which serum insulin levels are maintained near hyperinsulinemic baseline (Maintenance Hyperinsulinemia or \"MH\" Protocol) and the other in which serum insulin levels are lowered by 50% (Reduction toward Euinsulinemia or \"RE\" Protocol). In both clamps the investigators will use stable-isotope tracers to monitor hepatic glucose and triglyceride metabolism. The primary outcome will be the impact of steady-state clamp insulinemia on HGP vs DNL.",[36,473,474,43,475,27],"Hyperinsulinemia","Metabolic Dysfunction Associated Steatotic Liver Disease","Prediabetic State",[477,473,40,478,479],"Insulin resistance","Non-alcoholic fatty liver disease","Metabolic dysfunction associated steatotic liver disease","2026-02-04",{"date":482,"type":64},"2026-02-06",{"date":484,"type":21},"2027-01-01",{"date":486,"type":21},"2029-02-28",{"name":488,"class":71},"Columbia University",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":242,"minAge":18,"maxAge":243,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":501,"conditions":502,"keywords":505,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":72},"100556317","phase-4-effect-of-a-gnrh-analog-on-hepatic-steatosis-100556317","NCT06523530","Effect of a GnRH Analog on Hepatic Steatosis","Effect of the Pharmacological Cessation of Menstruation With a GnRH Analog on Hepatic Steatosis in Women With Endometriosis","EndomMASLD","Inclusion Criteria:\n\n* women of reproductive age\n* diagnosis of endometriosis. The disease is suspected by patient's individual history (chronic pelvic pain, dyspareunia or\u002Fand dysmenorrhea) and the ultrasonographic imaging (chocolate cysts). The diagnosis is confirmed histologically, after laparoscopic surgical treatment and biopsy sampling, which will be interpreted by an independent blinded pathologist.\n* use of contraceptives, which is the first line treatment, is contraindicated or the patient does not consent to receive contraceptives, due to personal preferences.\n* written informed consent to participate to the study\n\nExclusion Criteria:\n\n* mean ethanol consumption \\>10 g\u002Fday\n* history of other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and overlap syndromes, drug-induced liver injury, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)\n* liver cirrhosis\n* any malignancy\n* chronic kidney disease\n* uncontrolled hypothyroidism or hyperthyroidism\n* severe sexual hormone disorders (congenital adrenaline hyperplasia, Down syndrome, Turner syndrome).\n* use of the following medications within a 12-month period before baseline, which are associated with drug-induced liver injury (DILI): interferon, tamoxifen, amiodarone, aloperidin, glucocorticoids, hormone replacement therapy, contraceptives, anabolic steroids, any medication against tuberculosis, epilepsy or viruses, methotrexate, parenteral nutrition\n* use of the following medications within a 12-month period before baseline, which are probably associated with improvement in hepatic steatosis: vitamin E, pioglitazone, insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium- glucose co-transporter-2 inhibitors (SGLT-2i), orlistat, ursodeoxycholic acid\n* use of any GnRH agonist or antagonist within a 12-month period before baseline",{"count":498,"type":21},62,[500],"PHASE4","Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.",[31,503,504],"Nonalcoholic Fatty Liver","Endometriosis",[506,507,508,33,34,509,510,94,88,511,512,513,514],"endometriosis","goserelin acetate","hepatic fibrosis","metabolic dysfunction-associated steatotic liver disease","metabolic dysfunction-associated steatohepatitis","nonalcoholic fatty liver disease","nonalcoholic steatohepatitis","treatment","menopause","2026-02-01",{"date":517,"type":64},"2026-02-03",{"date":519,"type":64},"2024-11-26",{"date":521,"type":21},"2027-10",{"name":523,"class":71},"Aristotle University Of Thessaloniki",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":532,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":147},"100622256","early-phase-1-efficacy-and-safety-of-rifaximin--in-treating-masld-100622256","NCT07381257","Efficacy and Safety of Rifaximin-α in Treating MASLD","Efficacy and Safety of Rifaximin-α in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Open-Label, Controlled Pilot Clinical Trial","Inclusion Criteria\n\n1. Willingness to provide written informed consent.\n2. Aged 18 to 75 years, inclusive, regardless of gender.\n3. Diagnosis of hepatic steatosis (fatty liver) within the past 6 months.\n4. Presence of at least one metabolic\u002Fcardiovascular risk factor:\n\n   A. BMI ≥ 23.0 kg\u002Fm², or waist circumference ≥ 90 cm (male) \u002F 80 cm (female). B. Fasting plasma glucose (FPG) ≥ 5.6 mmol\u002FL, or 2-hour postprandial glucose ≥ 7.8 mmol\u002FL, or HbA1c ≥ 5.7%, or documented history of type 2 diabetes mellitus (T2DM) or current use of anti-diabetic medication.\n\n   C. Fasting serum triglycerides (TG) ≥ 1.70 mmol\u002FL, or current use of medication for hypertriglyceridemia.\n\n   D. Serum high-density lipoprotein (HDL) cholesterol ≤ 1.0 mmol\u002FL (male) and ≤ 1.3 mmol\u002FL (female), or current use of lipid-lowering medication.\n\n   E. Blood pressure ≥ 130\u002F85 mmHg, or current use of antihypertensive medication.\n5. Liver fat content ≥ 8% as measured by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF).\n\nExclusion Criteria\n\n1. Confirmed diagnosis of liver cirrhosis based on clinical, laboratory, imaging, and\u002For liver biopsy findings.\n2. Evidence of other specific etiologies of chronic liver disease confirmed by history or laboratory tests, including but not limited to: viral hepatitis (B or C, etc.), autoimmune liver disease, alcohol-related liver disease (defined as \\>20 g\u002Fday for females or \\>30 g\u002Fday for males), drug-induced liver injury, Wilson's disease, alpha-1 antitrypsin deficiency, or hereditary hemochromatosis.\n3. Other identifiable causes of hepatic steatosis confirmed by history or laboratory tests, such as: specific medications (e.g., tamoxifen, amiodarone, valproate, methotrexate, glucocorticoids, olanzapine), total parenteral nutrition, hypothyroidism, inflammatory bowel disease, Cushing's syndrome, celiac disease, abetalipoproteinemia, lipodystrophic diabetes, Mauriac syndrome, hypopituitarism, hypogonadism, polycystic ovary syndrome, etc.\n4. Use of medications known to alter gut microbiota (e.g., lactulose, systemic antibiotics, any intestinal microecological preparations) within 4 weeks prior to screening.\n5. Dose of hepatoprotective or lipid-lowering medications not stabilized for at least 4 weeks prior to screening.\n6. Received any Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or remeglutide treatment within 12 weeks prior to screening, or plans to receive such treatment during the study.\n7. Dose of medications that may affect MASLD, anti-diabetic agents (excluding GLP-1 RAs and remeglutide), or weight-loss drugs not stabilized for at least 12 weeks prior to screening.\n8. Self-reported weight change \\>5% within 4 weeks prior to screening.\n9. BMI \\> 35 kg\u002Fm².\n10. Poorly controlled glycemia: HbA1c \\> 9%.\n11. Total bilirubin \\> 1.5 mg\u002FdL (except with normal direct bilirubin), or Alanine Aminotransferase (ALT) \\> 5 times the Upper Limit of Normal (ULN), or Aspartate Aminotransferase (AST) \\> 5 times ULN, or Alkaline Phosphatase (ALP) \\> 2 times ULN.\n12. Estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m².\n13. History of or planned bariatric\u002Fmetabolic therapy, including but not limited to endoscopic interventions, surgical procedures, or Traditional Chinese Medicine therapies. Exceptions may be made if previous interventions have been reversed or removed (e.g., intragastric balloon, subcutaneous threads) for more than 12 weeks.\n14. History of or current hepatocellular carcinoma (HCC).\n15. Diagnosis of any malignancy within the past 5 years, except for malignancies with low risk of metastasis or death (estimated 5-year overall survival \\>90%), such as effectively treated early-stage gastrointestinal cancer, carcinoma in situ of the cervix, non-melanoma skin cancer, or localized prostate cancer.\n16. Significant comorbid conditions affecting the cardiovascular, respiratory, rheumatological\u002Fimmunological, hematological, biliary, or pancreatic systems; or history of myocardial infarction, stroke, heart failure, unstable angina, or transient ischemic attack within 6 months prior to screening; or presence of psychiatric disorders.\n17. HIV infection.\n18. Known allergy or hypersensitivity to rifaximin.\n19. Contraindications to MRI, such as incompatible metallic implants, claustrophobia, or body size exceeding scanner capacity.\n20. Pregnant or lactating women, women of childbearing potential not using effective contraception, or individuals planning pregnancy.\n21. Participation in another investigational drug trial within 3 months prior to screening.\n22. Any other condition deemed by the investigator to be unsuitable for participation in the study.",{"count":272,"type":21},[533],"EARLY_PHASE1","Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences MASLD progression.\n\nTarget Population: Patients diagnosed with MASLD. Intervention: This trial is a multicenter, prospective, randomized, controlled study. Enrolled MASLD patients who meet the inclusion criteria, do not meet any exclusion criteria, and provide written informed consent will be randomized in a 2:1 ratio to the Rifaximin-α treatment group (40 cases) or the control group (20 cases). All patients are advised to maintain daily physical activity and follow a recommended dietary plan (e.g., Mediterranean diet). The Rifaximin-α treatment group will receive oral Rifaximin-α at a dose of 1200 mg per day for 24 weeks. Both groups of patients will enter a 24-week follow-up period after completing the 24-week treatment. During the study, patients' existing foundational treatments (such as liver-protecting, lipid-lowering, glucose-lowering, and antihypertensive therapies) will be maintained. Relevant indicators will be closely monitored. And avoid the use of medications known to alter the gut microbiota, such as lactulose, antibiotics, and various types of intestinal microecological preparations.\n\nInvestigational Drug: Rifaximin-α (Alfa Wassermann S.p.A., Italy).",[31],[31,537],"Rifaximin","2026-01-23",{"date":540,"type":64},"2026-02-02",{"date":542,"type":21},"2026-01-15",{"date":544,"type":21},"2027-12-31",{"name":546,"class":71},"Shanghai Changzheng Hospital",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":323,"sex":17,"minAge":554,"maxAge":119,"enrollmentInfo":555,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":147},"100621680","ultrasound-liver-imaging-for-classification-of-metabolic-dysfunction-associated-steatotic-liver-disease-100621680","NCT07373769","Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease","Multi-modal, Multi-parametric Liver Imaging for Ultrasound-based Stratification of Patients With MAFLD","Inclusion Criteria:\n\n* Participants between the ages of 19 and 75.\n* healthy volunteers and have no known history of liver disease\n* patients with chronic liver disease, with fibrosis stages F0, F1, F2, F3 or F4.\n\nExclusion Criteria:\n\nDoes not speak and\u002For read English\n\nCANNOT undergo an MRI exam for one of the following reasons:\n\n* Retained wires from an electronic implant that has been removed (i.e. pacemaker wires not attached to a pacemaker)\n* Cardiac pacemaker or defibrillator\n* Metal in eye or orbit\n* Ferromagnetic aneurysm clip\n* Pregnancy\n* Makeup tattoos that are not designed to fade over time\n* Stainless steel intrauterine device (IUD)\n\nDepending on the individual situation, patients MAY NOT be able to participate the MRI exam if they have\u002Fhad any of the following:\n\n* Artificial heart valve\n* Ear or eye implant\n* Brain aneurysm clip\n* Implanted electronic device (i.e. drug infusion pump, electrical stimulator)\n* Coil, catheter, or filter in any blood vessel\n* Orthopedic hardware (artificial joint, plate, screw, rod)\n* Shrapnel, bullets, or other metal fragments\n* Surgery, medical procedure or tattoos (including tattooed eyeliner) in the last six weeks\n* Other metallic prostheses","19 Years",{"count":556,"type":21},145,"Tissue elasticity and viscosity correlate with pathology. These tissue properties are typically evaluated subjectively using palpation. The purpose of \"elastography\" is to provide an objective elasticity image that is equivalent to the remote palpation of tissue. The investigators have developed elastography imaging systems based on ultrasound and magnetic resonance imaging and have applied them previously to prostate imaging, breast imaging in patients and liver imaging in healthy volunteers.\n\nA first objective of this study is to compare the investigators' ultrasound shear wave absolute vibro-elastography (S-WAVE) technology with the existing clinical standard, FibroScan, and magnetic resonance elastography to quantify liver stiffness in healthy volunteers and in patients suspected of fatty liver disease.\n\nA second objective of this study is to compare ultrasound-based liver tissue fat measurement with MRI-based measurements.\n\nA third objective of this study is to determine whether ultrasound can be used to assess liver inflammation.",[31],[560,561,164,562,563],"steatosis","fibrosis","inflammation","liver",{"date":565,"type":64},"2026-01-28",{"date":567,"type":21},"2026-01-01",{"date":569,"type":21},"2032-07-01",{"name":571,"class":71},"University of British Columbia",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":580,"enrollmentInfo":581,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":583,"conditions":584,"keywords":587,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":72},"100582875","study-of-the-link-between-mash--metabolic-dysfunction-associated-steatohepatitis-and-mams-mitochondria-associated-membranes--alteration-in-patients-undergoing-bariatric-surgery---mamba-100582875","NCT06868992","Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA","Study of the Link Between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) Alteration in Patients Undergoing Bariatric Surgery - MAMBA","MAMBA","* Inclusion Criteria \\* :\n\n  * Female or male adult patients\n  * Patient who has benefited from a pluridisciplinary evaluation (medical, surgical, psychiatric), with a favorable opinion for a sleeve gastrectomy or a gastric bypass.\n  * Patient with an indication Indication for intraoperative liver biopsy due to suspected MASH\n  * Patient who agrees to be included in the study and who signs the informed consent form,\n  * Patient affiliated to a healthcare insurance plan.\n* Exclusion Criteria \\* :\n\n  * Patient presenting Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).\n  * Patient presenting previous or current infection with Hepatitis C\n  * Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.\n  * Patient presenting Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.\n  * Patient presenting Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease.\n  * Patient presenting Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency.\n  * Patient presenting Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y\u002FH63D.\n  * Patient presenting Drug-induced liver disease as defined on the basis of typical exposure and history.\n  * Patient presenting Bile duct obstruction as shown by imaging studies.\n  * History of ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, methotrexate, amiodarone or tetracycline in the previous 6 months.\n  * Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices\n  * Consommation régulière et\u002Fou excessive d'alcool (plus de 30g\u002Fj pour les hommes et plus de 15 g\u002Fj pour les femmes) sur une période de plus de 2 ans au cours des 10 dernières années.\n  * History of known HIV infection\n  * History of type 1 diabetes\n  * Pregnant women or breastfeeding mothers\\*.\n  * Minor patient\n  * Patient deprived of liberty,\n  * Patients under psychiatric care\n  * Patients admitted to a health or social care establishment for purposes other than research\n  * Mentally unbalanced patients, under supervision or guardianship,\n  * Patients not affiliated to a social security scheme or benefiting from a similar scheme\n  * Patient who does not understand French\u002F is unable to give consent,\n  * Patient already included in a trial who may interfere with the study","99 Years",{"count":582,"type":21},20,"The main research hypothesis is that alterations in the communication between the endoplasmic reticulum (ER) and the mitochondria at contact sites called mitochondria-associated membranes (MAMs) occurs in different hepatic cell types of patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD) and is involved in the progression towards MASH and could also influence the process of improvement of MASH.\n\nThis study aims to investigate the link between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) in liver cells and peripheral blood mononuclear cells (PBMCs) in patients undergoing bariatric surgery. The primary objective is to analyze MAMs alterations in hepatocytes in MASH patients compared to non-MASH patients. Secondary objectives include evaluating the correlation between MAMs in PBMCs and liver cells and assessing MAMs changes post-bariatric surgery.",[31,32,585,586],"Sleeve Gastrectomy","Gastric Bypass Surgery",[34,33,588,589,590],"Mitochondria-Associated Membranes (MAMs)","Bariatric Surgery","Hepatic Fibrosis","2026-01-14",{"date":542,"type":64},{"date":594,"type":64},"2025-04-15",{"date":596,"type":21},"2028-03",{"name":598,"class":71},"Hospices Civils de Lyon",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":606,"maxAge":18,"enrollmentInfo":607,"targetDuration":4,"studyType":22,"phases":609,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":618,"locationsCount":147},"100575125","effect-of-indianized-version-of-mediterranean-diet-vs-low-fat-diet-on-hepatic-steatosis-in-overweight-children-and-adolescent-with-masld-100575125","NCT06768216","Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD","Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD: A Randomized Control Trial","Inclusion Criteria:\n\n1. Age: 8-18 years\n2. BMI \\> 85th centile\n3. CAP \\> 236\n\nExclusion Criteria:\n\n\\- Other Liver diseases such as Viral hepatitis (Hep B and C), Autoimmune hepatitis, Wilson disease.","8 Years",{"count":608,"type":21},134,[24],"NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis. A high prevalence of NAFLD (62.5%) was observed in overweight\u002Fobese Indian adolescent (1). Lifestyle modification consisting of diet, exercise and weight loss has been advocated to treat patients with NAFLD (2). EASL guidelines recommends that the macronutrient in the diet should be adjusted according to the Mediterranean diet for weight loss (3). Mediterranean diet helps to decrease hepatic fat by decreasing lipogenesis, fibrogenesis, inflammation, oxidative stress and by increasing fatty acids beta oxidation (4). There are various studies showing benefits of using other diets such as Low Fat Diet, Low Carbdohydrate diet, Low Fructose Diet, et. Though there are numerous studies in adults comparing Mediterranean diet vs Low Fat diet, date regarding the same in children are lacking. The aim of this study will be to compare the Effect of Indianized version of Mediterranean diet vs. Low Fat Diet on Hepatic Steatosis in Overweight children and adolescent with MASLD.",[31],"2025-12-31",{"date":614,"type":64},"2026-01-06",{"date":616,"type":64},"2025-02-15",{"date":386,"type":21},{"name":619,"class":71},"Institute of Liver and Biliary Sciences, India",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":629,"briefSummary":630,"conditions":631,"keywords":633,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":642,"leadSponsor":644,"locationsCount":72},"100607715","quantitative-ultrasounddeepusff-vs-mri-pdff-for-liver-fat-assessment-in-masld-100607715","NCT07192159","Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD","Evaluation of a Quantitative Ultrasound Model(DeepUSFF) for Liver Fat Quantification in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Prospective Study Using MRI-PDFF as the Reference Standard","DeepUSFF","Inclusion Criteria:\n\n* Patients with clinically suspected MASLD based on abnormal ultrasound or liver function tests requiring liver ultrasound or MRI examination\n* BMI ≥25 kg\u002Fm² or waist circumference \\>90 cm (male) or \\>80 cm (female), suggesting high likelihood of fatty liver disease\n* Living liver transplant donors requiring preoperative liver ultrasound or MRI examination\n* Age ≥18 years\n* Understanding and signing informed consent\n\nExclusion Criteria:\n\n* Significant alcohol consumption in the past 2 years:\n\nMale: ≥30-60g\u002Fday average alcohol intake Female: ≥20-50g\u002Fday average alcohol intake\n\n-Chronic liver disease:\n\nHistological diagnosis of chronic liver disease HBsAg positive Anti-HCV positive Other suspected chronic liver diseases\n\n-Liver failure:\n\nSerum albumin \\\u003C3.2 g\u002FdL INR \\>1.3 Direct bilirubin \\>1.3 mg\u002FdL\n\n* History of esophageal varices, ascites, hepatic encephalopathy, or acute biliary obstruction\n* History of liver cancer diagnosis or treatment\n* History of liver surgery\n* Pregnancy\n* Inability to obtain adequate liver ultrasound imaging:\n\nPatient cooperation impossible Inadequate image acquisition as determined by investigator\n\n-Inability to obtain adequate liver MRI imaging: Patient cooperation impossible Severe obesity preventing MRI examination MRI contraindications (cardiac pacemaker, etc.) Other factors preventing adequate imaging as determined by investigator",{"count":498,"type":21},[24],"This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat quantification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study will compare the diagnostic accuracy of quantitative ultrasound imaging against MRI-PDFF as the reference standard.",[31,95,632],"Liver Disease Parenchymal",[164,334,634,635,636,637],"MRI-PDFF","Liver fat quantification","Hepatic steatosis","Deep learning","2025-09-17",{"date":640,"type":64},"2025-09-25",{"date":66,"type":64},{"date":643,"type":21},"2026-06-30",{"name":344,"class":71},{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":323,"sex":17,"minAge":653,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":22,"phases":656,"briefSummary":657,"conditions":658,"keywords":661,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":147},"100603233","how-abnormal-function-of-fat-tissue-in-type-1-diabetes-contributes-to-fat-in-the-liver-100603233","NCT07133854","How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver","The Impact of Adipose Tissue Insulin Resistance and Abdominal Obesity on Hepatic Fatty Acid Metabolism in Type 1 Diabetes","AGL14","Inclusion Criteria:\n\n* 16 individuals living with T1D and abdominal obesity, as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria (https:\u002F\u002Fwww.idf.org\u002Fe-library\u002Fconsensus-statements\u002F60- \\[1\\]. Treatment for T1D will be intensive insulin therapy on continuous pump perfusion with continuous glucose monitoring.\n* 16 individuals with normoglycemia (i.e., HbA1c below 6.0%) matched for sex, age (± 5 years), waist circumference (± 3 cm), and menopausal status.\n\nExclusion Criteria:\n\n* less than 70% of time in glycemic range (for T1D);\n* history of primary dyslipidemia (LDL-cholesterol over 5 mmol\u002FL or TG over 10 mmol\u002FL) or uncontrolled high blood pressure (over 160\u002F100 mmHg) precluding the withdrawal of lipid lowering and anti-hypertensive agents as per protocol;\n* presence of overt cardiovascular, liver or renal disease (except microalbuminuria without reduced kidney function), or other uncontrolled medical conditions;\n* use of any medication other than insulin that may affect lipid or carbohydrate metabolism and that cannot be stopped prior to testing;\n* current or planned pregnancy within the next 6 months;\n* any contraindication to MRI.\n* Being allergic to eggs\n* Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day\n* Having participated to a research study with exposure to radiation in the last year before the start of the study","21 Years",{"count":655,"type":21},32,[24],"Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.",[31,659,660],"Non-Alcoholic Steato-Hepatitis (NASH)","Type 1 Diabetes Mellitus",[662,663],"abdominal obesity","Adipose tissue insulin resistance","2025-08-13",{"date":666,"type":64},"2025-08-21",{"date":668,"type":21},"2026-09",{"date":670,"type":21},"2028-12",{"name":672,"class":71},"Université de Sherbrooke",{"id":674,"slug":675,"hasResults":12,"nctId":676,"briefTitle":677,"officialTitle":678,"acronym":679,"eligibilityCriteria":680,"healthyVolunteers":323,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":681,"targetDuration":4,"studyType":22,"phases":683,"briefSummary":684,"conditions":685,"keywords":693,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":701,"lastUpdatePostDateStruct":702,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":314},"100600119","the-impact-of-pectin-supplementation-on-systematic-inflammation-pathway-gut-microbiome-and-metabolic-health-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100600119","NCT07093346","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study","PEC-MASLD","Inclusion Criteria:\n\nInclusion criteria for the main study:\n\n* Patients with clinical diagnosis of MASLD (formerly termed non-alcoholic fatty liver disease (NAFLD)), having assessment suggesting that liver fat \\> 5% (e.g. histological evidence or\u002F and Transient Elastography using Controlled Attenuation Parameter (CAP)- FibroScan™ in the past month and\u002For liver imaging (such as ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI)).\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years who have a body mass index (BMI) between 18.5 and 39.9 kg\u002Fm2 and stable weight (weight gain or loss ≤ 3kg) for the past 3 months.\n* For diabetic participants: controlled blood glucose levels Haemoglobin A1C (HbA1c) \\\u003C7.0% (\\\u003C53 mmol\u002Fmol) \\[1\\].\n* Able to undergo CAP-FibroScan™.\n\nInclusion criteria for healthy participants who will have MRI scans:\n\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years.\n* participants with CAP\\\u003C250 kpa\\\u003C8kP by a FibroScan™ within the past 6 months.\n\nExclusion Criteria:\n\nExclusion criteria for the main study:\n\n* Have allergy toward soya, milk or chocolate.\n* Have allergy toward pectin.\n* Participants on vegan diet.\n* Have eating disorders or difficulties or gastrointestinal conditions e.g. malabsorptive conditions such as coeliac, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) or gastroparesis.\n* Have chronic malnutrition condition.\n* History of major surgery which potentially limits participation or completion of the study.\n* History of previous intestinal surgery known to affect food intake or digestive function, including bariatric surgery.\n* Use of antibiotics, antifungal medications, probiotics or prebiotics 90 days before the start of the study.\n* Are taking the following medications: immunosuppressants, amiodarone and\u002For perhexiline.\n* Are currently following or anticipated to commence a specialised commercially available weight loss diet and\u002For program or concomitant use of any weight loss medication or herbal weight loss products.\n* History of side effects towards probiotics or prebiotics.\n* History or current psychiatric illness.\n* History or current neurological condition (e.g. epilepsy).\n* Participants with other liver abnormalities.\n* Evidence of monogenic metabolism diseases such as Lysosomal acid lipase deficiency (LALD), Wilson disease, Hypobetalipoproteinemia, or inborn errors of metabolism.\n* Have had a weight change exceeding 3 kg within 3 months.\n* Uncontrolled diabetes, active malignancy, or chronic infections.\n* Having symptoms of active infection.\n* Excessive alcohol intake defined as self-reported intakes greater than 21 units per week in men, and 14 units per week in women.\n* Participants who are pregnant, breast feeding or actively planning pregnancy will be excluded from the study.\n* Participation in any other trial in the last 3 months.\n\nExclusion criteria for healthy volunteers MRI scans and patients optional MRI scans:\n\n* Contraindications for MRI scanning: having pacemakers, defibrillators, neurostimulators, prohibited medical implants, and foreign bodies (e.g. bullets, shrapnel, metal slivers), history of metallic foreign body in eye(s) and penetrating eye injury that could present a risk during an MRI scan.\n* Difficulty breathing or inability to lie flat, as well as conditions that could worsen under stress (such as anxiety or panic disorders, claustrophobia, uncontrolled hypertension, or seizure disorders) severe enough to prevent undergoing an MRI.",{"count":682,"type":21},45,[24],"The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:\n\n-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?\n\nResearchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.\n\nParticipants will:\n\n* Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control)\n* Provide stool and fasting blood samples before and after the intervention\n* Undergo anthropometric measurements (weight, height, waist\u002Fhip ratio, and blood pressure)\n* Complete a case report form (CRF) including demographics and health\u002Fmedical history\n* Undergo a FibroScan™ to assess liver health\n* (Optional) Participate in MRI scans to evaluate gut permeability",[686,687,688,33,94,31,689,690,691,692],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Fatty Liver Disease (NAFLD)","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","NAFLD (Nonalcoholic Fatty Liver Disease)","NAFLD (Non-alcoholic Fatty Liver Disease)","NAFLD - Non-Alcoholic Fatty Liver Disease","NAFLD - Nonalcoholic Fatty Liver Disease",[694,695,33,94,686,696,697,698,699,700,31],"LM pectin","pectin","Systemic Inflammatory Response","Dietary Fiber","Dietary Fibre","Diet","gut microbiota","2025-07-22",{"date":703,"type":64},"2025-07-30",{"date":705,"type":64},"2025-06-10",{"date":707,"type":21},"2027-03-31",{"name":709,"class":71},"University of Nottingham",{"id":711,"slug":712,"hasResults":12,"nctId":713,"briefTitle":714,"officialTitle":715,"acronym":4,"eligibilityCriteria":716,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":717,"enrollmentInfo":718,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":720,"conditions":721,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":727,"leadSponsor":729,"locationsCount":731},"100599304","prognostic-model-for-masld-related-cirrhosis-100599304","NCT07082751","Prognostic Model for MASLD Related Cirrhosis","Prognostic Model for Metabolic Dysfunction-associated Steatotic Liver Disease Related Cirrhosis","Inclusion Criteria:\n\n1\\. Men and women aged between 18 and 80 years (inclusive) who understand and sign informed consent forms; 2. Compensated MASLD-related cirrhosis diagnosis(meet one of the following conditions):\n\n1. The liver biopsy during the screening period (liver biopsy within 6 months of screening is acceptable) showing cirrhosis with steatohepatitis according to the Non Alcoholic Fatty Liver Disease Clinical Research Network (NASH-CRN) scoring system, and there is no evidence of competitive aetiology.\n2. The liver biopsy during the screening period (liver biopsy within 6 months of screening is acceptable) showing cirrhosis with steatosis (no steatohepatitis) according to NASH-CRN scoring system, and there is no evidence of competitive aetiology. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including overweight\u002Fobesity and\u002For prediabetes\u002Ftype 2 diabetes mellitus (T2DM).\n3. Historical biopsy showed steatohepatitis, and now diagnosed with cirrhosis through non-invasive tests or clinical criteria (see criterion (6)-1)). There is no evidence of competing aetiology. There is at least 1 coexisting or history of metabolic comorbidity.\n4. Historical biopsy showed steatosis (no steatohepatitis), and now diagnosed with cirrhosis through non-invasive tests or clinical criteria (see criterion (6)-1)). There is no evidence of competing aetiology. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including overweight\u002Fobesity and\u002For prediabetes\u002Ftype 2 diabetes mellitus (T2DM).\n5. 'Cryptogenic cirrhosis' (with no evidence of hepatic steatosis on both histopathology and imaging). There is no evidence of competing aetiology. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including overweight\u002Fobesity and\u002For prediabetes\u002Ftype 2 diabetes mellitus (T2DM).\n6. MASLD-related cirrhosis is defined based on the following criterias:\n\n   a. Cirrhosis is defined based on one of the following non-invasive tests(NITS): i: MRE ≥ 5kPa or VCTE-LSM ≥ 20kPa; ii:VCTE ≥15 kPa and \\\u003C20 kPa and 1 of the following: MRE≥4.2kPa or Agile4≥0.565 or Platelets≤150,000\u002FµL; iii: VCTE \\\u003C15 kPa and 2 of the following: MRE≥4.2kPa or Agile4≥0.565 or Platelets≤150,000\u002FµL; b. Current or previous imaging examinations have diagnosed fatty liver or controlled attenuation parameter (CAP)≥288dB\u002Fm or magnetic resonance imaging proton density fat fraction (MRI-PDFF)≥5%.\n\n   c. There is no evidence of competing aetiology; d. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including overweight\u002Fobesity and\u002For prediabetes\u002Ftype 2 diabetes mellitus (T2DM).\n\n   Exclusion Criteria:\n   * 1\\. Other chronic liver diseases (including but not limited to viral hepatitis, alcoholic liver disease, drug-induced liver injury, autoimmune liver disease, Wilson's disease, hemochromatosis, etc.) 2. There has been a continuous history of heavy drinking for 3 months or more current or rencent 5 years (heavy drinking is defined as \\>20 g\u002Fday in women and \\>30 g\u002Fday in men); Or researchers can not reliably quantify alcohol consumption.\n\n     3\\. Hepatic decompensation events (including ascites, esophageal and gastric variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, etc.) or hepatocellular carcinomaor.\n\n     4\\. Previous (\\\u003C5 years before screening) treatment for obesity with surgery; 5. Have obesity induced by other endocrinologic disorders (i.e. Cushing Syndrome) genetic diseases; 6. Secondary factors that can cause liver steatosis, such as malnutrition, medication, genetic metabolic diseases, etc.\n\n     7\\. Positive for human immunodeficiency virus (HIV) infection; 8. History of drug use or abuse of drugs within the 12 months prior to screening.\n\n     9\\. Pregnant or lactating women; 10. Researchers believe that patients who are not suitable to participate in this study.","80 Years",{"count":719,"type":21},228,"This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months. The primary endpoint was cumulative incidence of liver-related events (including decompensation events, hepatocellular carcinoma, liver transplantation, and liver-related mortality) and all-cause mortality. Secondary endpoints included cumulative incidence of metabolic events and changes in non-invasive fibrosis markers.",[474,722],"Compensated Cirrhosis","2025-07-16",{"date":725,"type":64},"2025-07-24",{"date":664,"type":21},{"date":728,"type":21},"2030-06-30",{"name":730,"class":71},"Beijing Friendship Hospital",9]